Robert Lavender Institution Verified
Sourced from institutional research profiles (UAMS TRI or ARA).
Professor
University of Arkansas for Medical Sciences
faculty
Internal Med, College of Medicine
Research Areas
Biography and Research Information
OverviewAI-generated summary
Robert Lavender is a Professor in the Department of Internal Medicine at the University of Arkansas for Medical Sciences. His research focuses on various aspects of health sciences and medical education. He has been involved in studies related to health disparities and outcomes, as well as innovations in medical education. His work also touches upon behavioral health and interventions, contributing to a broader understanding of health and well-being.
Grants & Funding
- A randomized, 24-week, open-label, 2-arm parallel-group, multicenter study comparing the efficacy and safety of insulin gargine/lixisenatide fixed rat Sanofi Pasteur, Inc. Principal Investigator
- A Phase III Randomized, double blind, parallel-group stuyd of the efficacy and safety of oral dabigatran etexilate (150 mg bid)compared to warffarin ( Boehringer Ingleheim Pharmaceuticals, Inc. Principal Investigator
- Protocol #11702 entitled: “Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep-vein thrombosis and/or pulmonary emboli Bayer Corporation (Bayer USA) Principal Investigator
- A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate cardiovascular outcomes during treatment with lixisenati Sanofi-Aventis Principal Investigator
- A Phase III Randomized, double blind, parallel-group stuyd of the efficacy and safety of oral dabigatran etexilate (150 mg bid)compared to warffarin ( Boehringer Ingleheim Pharmaceuticals, Inc. Principal Investigator
- A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multi-Center, Multi-National Study for the Evaluation of Efficacy and Safety of (LM Daiichi Pharmaceutical Corporation Principal Investigator
- A double-blind, placebo-controlled, parallel, multicenter study on extended VTE prophylaxix in acutely ill medical patients with prolonged immobilizat Aventis Pharmaceuticals, Inc. Principal Investigator
- A randomized, 24-week, open-label, 2-arm parallel-group, multicenter study comparing the efficacy and safety of insulin gargine/lixisenatide fixed rat Sanofi Pasteur, Inc. Principal Investigator
Frequent Collaborators
Similar Researchers
Based on overlapping research topics